Search research articles
Contact Us
Filters
Showing results (111-120 of 179) with videos related to
Page
of 18
Sort By:
Journal of the National Cancer Institute
|
March 22, 2001
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4
R Soni, T O'Reilly, P Furet, et al.
Biochemical and Biophysical Research Communications
|
April 30, 1992
Isolation of two distinct type I angiotensin II receptor genes
T S Elton, C C Stephan, G R Taylor, et al.
HIV Medicine
|
February 26, 2015
Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
J V Baker, N W Engen, K Huppler Hullsiek, et al.
Annals of Neurology
|
May 19, 2001
Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis
J Gieffers, D Pohl, J Treib, et al.
European Urology
|
February 15, 2001
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis
M Lein, K Jung, U Elgeti, et al.
HIV Medicine
|
May 7, 2005
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load
M Bickel, V Rickerts, C Stephan, et al.
The Journal of Antimicrobial Chemotherapy
|
September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients
M Bickel, A Bodtländer, G K Knecht, et al.
Der Urologe. Ausg. A
|
September 25, 2003
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]
C Stephan, B Vogel, H Cammann, et al.
International Journal of Cancer
|
March 10, 2000
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
M Lein, K Jung, C Laube, et al.
Breast Cancer Research and Treatment
|
February 28, 2006
Prediction of breast cancer using volatile biomarkers in the breath
Michael Phillips, Renee N Cataneo, Beth Ann Ditkoff, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 179) with videos related to
Sort By:
Page
of 18
Journal of the National Cancer Institute
|
March 22, 2001
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4
R Soni, T O'Reilly, P Furet, et al.
Biochemical and Biophysical Research Communications
|
April 30, 1992
Isolation of two distinct type I angiotensin II receptor genes
T S Elton, C C Stephan, G R Taylor, et al.
HIV Medicine
|
February 26, 2015
Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
J V Baker, N W Engen, K Huppler Hullsiek, et al.
Annals of Neurology
|
May 19, 2001
Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis
J Gieffers, D Pohl, J Treib, et al.
European Urology
|
February 15, 2001
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis
M Lein, K Jung, U Elgeti, et al.
HIV Medicine
|
May 7, 2005
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load
M Bickel, V Rickerts, C Stephan, et al.
The Journal of Antimicrobial Chemotherapy
|
September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients
M Bickel, A Bodtländer, G K Knecht, et al.
Der Urologe. Ausg. A
|
September 25, 2003
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]
C Stephan, B Vogel, H Cammann, et al.
International Journal of Cancer
|
March 10, 2000
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
M Lein, K Jung, C Laube, et al.
Breast Cancer Research and Treatment
|
February 28, 2006
Prediction of breast cancer using volatile biomarkers in the breath
Michael Phillips, Renee N Cataneo, Beth Ann Ditkoff, et al.
Page
of 18